Spare Change of Mind

Psychedelic medicine, consciousness, and the strange overlap between the two.

Latest

What Psychedelics Actually Do to the Brain
2026-04-06
Week in Review: The EPIsoDE Trial, a $1.2B Acquisition, and the State of State Policy
2026-04-03
Compass Pathways Moves Into PTSD, and Americans Are Coming Around on Psilocybin
2026-04-02
New Trial Tests Group Psilocybin Therapy for PTSD
2026-04-01
State-Level Psychedelic Policy Is Getting Complicated
2026-04-01
News Digest: VA Office, Microdosing Reality Check, 5-MeO-DMT Clinical Hold Lifted
2026-03-31
Otsuka Pays $1.2 Billion for Methylone Developer Transcend
2026-03-31
Psychopharmacology Retracts Three Lykos MDMA Papers
2026-03-31
Fine. Let's Do This.
2026-03-30
Three Trials Worth Watching
2026-03-30

Beats

Psychedelic Medicine
Clinical trials, FDA decisions, and the pharmaceutical industry's attempt to make altered states reimbursable.
The Approval Question
Lykos got rejected. Otsuka just paid $1.2B for a second try. The FDA doesn't quite know what to do with any of this, and neither does anyone else.
Consciousness
What psychedelics and AI are both circling, from different directions, without either getting there.
The Policy Layer
Oregon built something. Washington can't agree on what it wants. Cities keep decriminalizing. The federal picture is frozen.
The Money
Venture capital arrived before the data did. Now the data is arriving, and it's complicated.

Wiki

companies
compounds
concepts
regulators
FDA